CClinicalTrials.gg
TerminatedNCT00945802Updated May 27, 2021

FST-201 In The Treatment of Acute Otitis Externa

A Phase 3 interventional study of FST-201 (dexamethasone 0.1%) Otic Suspension and ciprofloxacin 0.3%, dexamethasone 0.1% in Acute Otitis Externa, sponsored by Shire. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-27.

Sponsored by Shire · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.

02

Conditions studied

  • Acute Otitis Externa
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Have a clinical diagnosis of AOE in one or both ears, defined as a clinical score of at least 1 for edema (0-3 scale), 2 for overall inflammation (0-3 scale) and 1 for tenderness (absent=0, present=1).
  • Be at least 18 years of age at Visit 1 (Day 1, Screening/Baseline) of either sex and any race.
  • Provide written informed consent or parental assent.
  • Be willing and able to follow all instructions and attend all study visits

Exclusion criteria

Exclusion Criteria:

All subjects must not:

  • Have known sensitivity to any component of the study medications
  • Have a current infection requiring systemic antimicrobial treatment
  • Have used topical or systemic pain meds on the same day as Screening/Baseline Visit 1 and for the duration of the study.
  • Take any systemic (within 30 days) or otic corticosteroids (within 1 days) prior to Screening/Baseline Visit 1
  • Current use of topical or systemic non-steroidal or other anti-inflammatory drugs.
  • Use any topical otic treatment with alcohol, vinegar, hydrogen peroxide or other astringent medication during the course of the study or on the same day as Screening/Baseline Visit 1
  • Have taken any antibiotics within 3 days prior to Visit 1
  • Have signs and symptoms of AOE for > 4 weeks at Screening/Baseline Visit 1
  • Have a non-intact or perforated tympanic membrane in the enrolled ear
  • Have a clinical diagnosis of chronic suppurative otitis media, acute otitis media or acute otorrhea in patients with tympanostomy tubes
  • Have a clinical diagnosis of malignant otitis externa
  • Have overt fungal AOE
  • Have a viral infection of the pinna or tympanic membrane (i.e herpes zoster)
  • Have congenital abnormalities of the external auditory canal in the enrolled ear(s)
  • Have obstructive bony exostoses in the enrolled ear(s)
  • Have mastoid or other suppurative, non-infectious ear disorders (e.g, cholesteatoma)
  • Have malignant tumors of the external auditory canal
  • Have a history of otologic surgery. Surgery performed more than 1 year prior to Screening/Baseline Visit 1and limited to the tympanic membrane is allowed
  • Have seborrheic dermatitis of the external auditory canal
  • Have a current or prior history of immunosuppressive disorders
  • Have acute or chronic renal insufficiency, hepatitis or diabetes mellitus
  • Be pregnant, nursing or planning a pregnancy.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    FST-201 (dexamethasone 0.1%) Otic Suspension

    Drug: FST-201 (dexamethasone 0.1%) Otic Suspension

  • Active comparator
    ciprofloxacin 0.3%, dexamethasone 0.1%

    Drug: ciprofloxacin 0.3%, dexamethasone 0.1%

Interventions

  • DrugFST-201 (dexamethasone 0.1%) Otic Suspension

    Instill four drops two times a day

  • Drugciprofloxacin 0.3%, dexamethasone 0.1%

    Instill four drops two times a day

    Also known as: Ciprodex

05

What researchers measure

Primary outcomes

  1. Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.

    Time frame: 1 year

Secondary outcomes

  1. Microbiological resolution defined as elimination of pre-treatment pathogenic bacteria.

    Time frame: 1 year

06

Study locations

6 sites
  • ENT Associates of South Florida
    Boynton Beach, Florida 33426, United States
  • Sarasota, Florida 34239, United States
  • Austin Ear, Nose, and Throat Clinic
    Austin, Texas 78705, United States
  • San Antonio Ear, Nose, and Throat Research
    San Antonio, Texas 78215, United States
  • San Antonio Ear, Nose, and Throat Research
    San Antonio, Texas 78229, United States
  • Ear Institute of Texas
    San Antonio, Texas 78258, United States
07

Registry details

Key details

Study ID
NCT00945802
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 24, 2009
Start date
Jul 31, 2009
Primary completion
Jul 31, 2010
Completion
Jul 31, 2010
Last update
May 27, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion